Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Carcinoid tumour
- Focus Therapeutic Use
- 07 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 20 Jan 2017 Planned End Date changed from 1 Jan 2017 to 7 Jan 2018.